Literature DB >> 17151191

UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics.

Zhiming Wen1, Melanie N Tallman, Shazia Y Ali, Philip C Smith.   

Abstract

Etoposide, an important anticancer agent, undergoes glucuronidation both in vitro and in vivo. In this study, three isomeric glucuronides of etoposide, including one phenolic (EPG) and two alcoholic glucuronides (EAG1 and EAG2), were biosynthesized in vitro with human liver microsomes (HLMs), and identified by liquid chromatography-electrospray ionization-mass spectrometry and confirmed by beta-glucuronidase cleavage. In vitro UDP-glucuronosyltransferase (UGT) reaction screening with 12 recombinant human UGTs demonstrated that etoposide glucuronidation is mainly catalyzed by UGT1A1. Although UGT1A8 and 1A3 also catalyzed the glucuronidation of etoposide, their activities were approximately 10 and 1% of UGT1A1. Enzyme kinetic study indicated that the predominant form of etoposide glucuronide in HLMs and human intestinal microsomes (HIMs) was EPG, whereas EAG1 and EAG2 were the minor metabolites, with approximately an 8 to 10% glucuronidation rate of EPG. For the formation of EPG, the V(max) of HLMs (110 pmol/min/mg protein) was very similar to that of recombinant UGT1A1 (124 pmol/min/mg protein), whereas the V(max) of HIMs (54.4 pmol/min/mg protein) was 2-fold lower than those of HIMs and UGT1A1. The K(m) values of HLMs (530 microM) and HIMs (608 microM) were 2-fold higher than that of UGT1A1 (285 microM). The V(max)/K(m) values for the formation of EPG were 0.21 and 0.09 microl/min/mg protein for HLMs and HIMs, respectively. The data indicated that UGT1A1 is principally responsible for the formation of etoposide glucuronides, mainly in the form of phenolic glucuronide, suggesting that etoposide can be used as a highly selective probe substrate for human UGT1A1 in vitro.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17151191     DOI: 10.1124/dmd.106.012732

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  18 in total

Review 1.  Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy.

Authors:  Jacqueline Ramírez; Mark J Ratain; Federico Innocenti
Journal:  Future Oncol       Date:  2010-04       Impact factor: 3.404

2.  Targeted precise quantification of 12 human recombinant uridine-diphosphate glucuronosyl transferase 1A and 2B isoforms using nano-ultra-high-performance liquid chromatography/tandem mass spectrometry with selected reaction monitoring.

Authors:  John K Fallon; Hendrik Neubert; Theunis C Goosen; Philip C Smith
Journal:  Drug Metab Dispos       Date:  2013-09-17       Impact factor: 3.922

3.  Unusual gastrointestinal and cutaneous toxicities by bleomycin, etoposide, and cisplatin: a case report with pharmacogenetic analysis to personalize treatment.

Authors:  Marzia Del Re; Tiziana Latiano; Leonardo Fidilio; Giuliana Restante; Franco Morelli; Evaristo Maiello; Romano Danesi
Journal:  EPMA J       Date:  2017-03-07       Impact factor: 6.543

4.  Quantification of human uridine-diphosphate glucuronosyl transferase 1A isoforms in liver, intestine, and kidney using nanobore liquid chromatography-tandem mass spectrometry.

Authors:  David E Harbourt; John K Fallon; Shinya Ito; Takashi Baba; Joseph K Ritter; Gary L Glish; Philip C Smith
Journal:  Anal Chem       Date:  2011-12-05       Impact factor: 6.986

5.  Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells.

Authors:  C Fahrmayr; J König; D Auge; M Mieth; M F Fromm
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

6.  Influence of UGT1A1 polymorphism on etoposide plus platinum-induced neutropenia in Japanese patients with small-cell lung cancer.

Authors:  Yutaka Negoro; Ryoichi Yano; Mari Yoshimura; Yoko Suehiro; Shinji Yamashita; Takaaki Kodawara; Kyohei Watanabe; Hitoshi Tsukamoto; Toshiaki Nakamura; Maiko Kadowaki; Miwa Morikawa; Yukihiro Umeda; Masaki Anzai; Tamotsu Ishizuka; Nobuyuki Goto
Journal:  Int J Clin Oncol       Date:  2018-10-17       Impact factor: 3.402

7.  Etoposide pathway.

Authors:  Jun Yang; Alessia Bogni; Erin G Schuetz; Mark Ratain; M Eileen Dolan; Howard McLeod; Li Gong; Caroline Thorn; Mary V Relling; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2009-07       Impact factor: 2.089

8.  Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases.

Authors:  Yong Liu; Jacqueline Ramírez; Larry House; Mark J Ratain
Journal:  Drug Metab Dispos       Date:  2010-01       Impact factor: 3.922

9.  Characterization of human hepatic and extrahepatic UDP-glucuronosyltransferase enzymes involved in the metabolism of classic cannabinoids.

Authors:  Anna Mazur; Cheryl F Lichti; Paul L Prather; Agnieszka K Zielinska; Stacie M Bratton; Anna Gallus-Zawada; Moshe Finel; Grover P Miller; Anna Radomińska-Pandya; Jeffery H Moran
Journal:  Drug Metab Dispos       Date:  2009-04-01       Impact factor: 3.922

10.  Pregnancy-Related Hormones Increase UGT1A1-Mediated Labetalol Metabolism in Human Hepatocytes.

Authors:  Raju Khatri; John K Fallon; Craig Sykes; Natasha Kulick; Rebecca J B Rementer; Taryn A Miner; Amanda P Schauer; Angela D M Kashuba; Kim A Boggess; Kim L R Brouwer; Philip C Smith; Craig R Lee
Journal:  Front Pharmacol       Date:  2021-04-15       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.